title: Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
abstract: BACKGROUND
  To characterize healthcare resource utilization and costs in patients with metastatic lung cancer receiving chemotherapy in the US.
  
  
  METHODS
  Using data from a large private multi-payer health insurance claims database (2000-2006), we identified all patients beginning chemotherapy for metastatic lung cancer. Healthcare resource use (inpatient, outpatient, medications) and costs were tallied over time from date of therapy initiation ("index date") to date of disenrollment from the health plan (in most instances, presumably due to death) or the end of the study period, whichever occurred first. Healthcare utilization and costs were characterized using Kaplan-Meier sample average methods.
  
  
  RESULTS
  The study population consisted of 4068 patients; mean (SD) age was 65 (11) years. Over a median follow-up of 334 days, study subjects averaged 1.5 hospital admissions, 8.9 total inpatient days, and 69 physician office and hospital outpatient visits. Mean (95% CI) cumulative total healthcare costs were $125,849 ($120,228, $131,231). Costs of outpatient medical services and inpatient care constituted 34% and 20% of total healthcare costs, respectively; corresponding estimates for outpatient chemotherapy and other medication were 22% and 24%.
  
  
  CONCLUSIONS
  Our study sheds additional light on the burden of metastatic lung cancer among patients receiving chemotherapy, in terms of total cost thru end of life as well as component costs by setting and type of service, and may be useful in informing medical resource allocation in this patient population.
authors.affiliation: Policy Analysis Inc (PAI), Four Davis Court, Brookline, MA 02445, USA.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Vera-Llonch
authors.forename: Derek
authors.initials: D
authors.lastname: Weycker
authors.forename: Andrew
authors.initials: A
authors.lastname: Glass
authors.forename: Sue
authors.initials: S
authors.lastname: Gao
authors.forename: Rohit
authors.initials: R
authors.lastname: Borker
authors.forename: Beth
authors.initials: B
authors.lastname: Barber
authors.forename: Gerry
authors.initials: G
authors.lastname: Oster
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000191:economics* / Q000706:statistics & numerical data; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D017281:Cost of Illness; D005500:Follow-Up Studies; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006302:Health Services Research; D006760:Hospitalization / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000473:pathology; D008875:Middle Aged; D009819:Office Visits / Q000191:economics* / Q000706:statistics & numerical data; D014481:United States; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents
references.citation: Br J Cancer. 2007 Aug 20;97(4):479-85
references.pmid: 17653077
references.citation: Biometrics. 1997 Jun;53(2):419-34
references.pmid: 9192444
references.citation: J Natl Cancer Inst. 2008 May 7;100(9):630-41
references.pmid: 18445825
references.citation: Med Care. 1999 Jul;37(7):706-11
references.pmid: 10424641
references.citation: Arch Intern Med. 2006 Feb 13;166(3):326-31
references.pmid: 16476873
references.citation: Lung Cancer. 2005 Nov;50(2):143-54
references.pmid: 16112249
references.citation: Am J Manag Care. 2008 Sep;14(9):565-71
references.pmid: 18778171
references.citation: Cancer. 2007 Dec 1;110(11):2511-8
references.pmid: 17955504
references.citation: Value Health. 2009 Jun;12(4):481-8
references.pmid: 18980633